A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients.
Phase of Trial: Phase II/III
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Pirfenidone (Primary)
- Indications Bronchiolitis obliterans
- Focus Therapeutic Use
- Acronyms EPOS
- 08 Dec 2016 Planned End Date changed from 1 Jun 2017 to 1 Oct 2019.
- 08 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Oct 2018.
- 12 Apr 2016 According to European Clinical Trials Database, there has been an amendment in the severity of the disease from grade 1-2 to grade 1-3.